MedPath

Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF)

Phase 4
Terminated
Conditions
Nephrogenic Systemic Fibrosis
Nephrogenic Fibrosing Dermopathy
Registration Number
NCT01078987
Lead Sponsor
Loma Linda University
Brief Summary

The purpose of this study is to evaluate the pathophysiology of nephrogenic fibrosing dermopathy (NFD)/nephrogenic systemic fibrosis (NSF).

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
12
Inclusion Criteria
  • diagnosed with NFD/NSF following a kidney transplant
  • diagnosed with NFD/NSF following a liver transplant
  • NFD/NSF and who have not had a kidney or liver transplant
  • diagnosed with NFD/NSF and who have not had a kidney or liver transplant
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Improve elasticity of skin, including increased range of motion of compromised joints due to leathery skinAssessed two weeks after each monthly course of plasmapheresis
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Loma Linda University Medical Center

🇺🇸

Loma Linda, California, United States

Loma Linda University Medical Center
🇺🇸Loma Linda, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.